A Phase II Study of Trastuzumab Deruxtecan (DS-8201A) in Adolescents and Young Adults with Recurrent HER2-Positive Osteosarcoma

Full Title

A Phase 1/2 study of DS-8201a (NSC# 807708, IND# 153036) in children, adolescents, or young adults with recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor (PEPN1924)(CIRB)

Purpose

This study is assessing the safety and effectiveness of the investigational drug trastuzumab deruxtecan (DS-8201A) in adolescents and young adults with osteosarcoma (bone cancer) that is positive for the HER2 protein and has come back after prior treatment. Trastuzumab deruxtecan includes an antibody (trastuzumab) linked to a chemotherapy drug (deruxtecan). Trastuzumab attaches to HER2-positive cancer cells in a targeted way and delivers deruxtecan to kill them. The treatment is given intravenously (by vein).